Market Place
Sourcing Support
AM-Pharma Initiates Phase 2 Trial of Ilofotase Alfa
16 Jan 2024 //
BUSINESSWIRE
AM-Pharma Announces Positive Data From Phase 1b Evaluating Ilofotase Alfa
11 Oct 2023 //
BUSINESSWIRE
AM-Pharma cuts staff, CEO leaves as lead asset redirected
27 Sep 2023 //
FIERCE BIOTECH
AM-Pharma Announces Updated Clinical Development Strategy
26 Sep 2023 //
BUSINESSWIRE
AM-Pharma to Present Data From Phase 3 REVIVAL Study at Conferences
09 Mar 2023 //
BUSINESSWIRE
AM-Pharma, once a Pfizer takeover target, flunks phase 3 trial
21 Oct 2022 //
FIERCEBIOTECH
AM-Pharma Publishes In Vivo AKI Study Demonstrating Ilofotase Alfa’s Mechanism
05 Jul 2022 //
BUSINESSWIRE
AM-Pharma to Participate in Upcoming Jefferies Healthcare Conference
06 Jun 2022 //
BUSINESSWIRE
AM-Pharma to Participate in SVB Leerink Biopharma Private Company Connect
22 Mar 2022 //
BUSINESSWIRE
AM-Pharma Announces Two Presentations at 27th CCN International Conference
07 Mar 2022 //
BUSINESSWIRE
AM-Pharma to Participate in Upcoming Investor and Scientific Conferences
02 Mar 2022 //
BUSINESSWIRE
AM-Pharma Appoints Lars Boesgaard as CFO; Establishes U.S. Affiliate AM-Pharma
15 Sep 2021 //
BUSINESSWIRE
AM-Pharma finds a new partner for its kidney drug
08 Sep 2021 //
ENDPTS
AM-Pharma &Kyowa Kirin Sign License Agreement Commercialization
07 Sep 2021 //
BIOSPACE
AM-Pharma Enrolls First Patient in Japan for Ongoing Phase III SA-AKI Trial
01 Jul 2021 //
BUSINESSWIRE
KBI Biopharma, AM-Pharma Enter Manufacturing Agreement
17 Jun 2021 //
CONTRACTPHARMA
KBI Biopharma Enters Commercial Manufacturing Agreement with AM-Pharma
17 Jun 2021 //
BUSINESSWIRE
AM-Pharma Appoints Martijn Negen as VP Commercial Strategy
15 Jun 2021 //
BUSINESSWIRE
AM-Pharma Announces Enrollment of the First Patient in REVIVAL Phase III
12 Nov 2020 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.